Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
The "poison chair" treatment for multiple sclerosis.
Decreased systemic IL-7 and soluble IL-7Rα in multiple sclerosis patients.
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.
Treatment Burden and Chronic Illness: Who is at Most Risk?
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.
[The overall assessment of the quality of the physical health of patients with multiple sclerosis after the application of physical therapy. Part 1].
Drugs@FDA
Rare onset symptoms in multiple sclerosis.
Prevalence of people who could benefit from augmentative and alternative communication (AAC) in the UK: determining the need.
The use of cytokine signature patterns: separating drug naïve, interferon and natalizumab-treated multiple sclerosis patients.
Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.
Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis.
Multiple sclerosis: Could Helicobacter pylori provide protection against multiple sclerosis?
Fumaric acid esters prevent the NLRP3 inflammasome-mediated and ATP-triggered pyroptosis of differentiated THP-1 cells.
Voiding Dysfunction in Multiple Sclerosis.
The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
Autoimmune myelopathies.
Measuring participation as defined by the World Health Organization in the International Classification of Functioning, Disability and Health. Psychometric properties of the Ghent Participation Scale.
Fumaric acid esters promote neuronal survival upon ischemic stress through activation of the Nrf2 but not HIF-1 signaling pathway.
Glial cells as drug targets: What does it take?
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells.
UCSF Seminar: "Imaging spinal cord gray matter atrophy in MS using SF-SIGMA. Is neuronal loss a key mediator of MS disability?"
Intrathecal interferon reduces exacerbations of multiple sclerosis.
CinnoVex home page

Pages